Stephens Reaffirms “Overweight” Rating for Actinium Pharmaceuticals (NYSE:ATNM)

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “overweight” rating reiterated by equities research analysts at Stephens in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $5.00 price target on the stock. Stephens’ target price would suggest a potential upside of 259.71% from the company’s current price.

Several other research analysts have also issued reports on the stock. B. Riley lowered shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $16.00 to $2.00 in a research note on Wednesday, August 7th. Maxim Group decreased their target price on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Actinium Pharmaceuticals in a report on Friday, November 15th. Finally, StockNews.com downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.40.

Actinium Pharmaceuticals Stock Down 2.1 %

Shares of ATNM opened at $1.39 on Tuesday. The business’s 50-day moving average is $1.77. Actinium Pharmaceuticals has a 1 year low of $1.33 and a 1 year high of $10.24. The company has a market capitalization of $43.36 million, a P/E ratio of -1.00 and a beta of 0.14.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several large investors have recently bought and sold shares of ATNM. The Manufacturers Life Insurance Company bought a new stake in shares of Actinium Pharmaceuticals during the 2nd quarter worth $92,000. Renaissance Technologies LLC purchased a new stake in Actinium Pharmaceuticals during the second quarter worth about $142,000. Interchange Capital Partners LLC purchased a new position in Actinium Pharmaceuticals in the third quarter valued at about $37,000. Rhumbline Advisers grew its position in shares of Actinium Pharmaceuticals by 23.4% during the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after acquiring an additional 7,525 shares during the period. Finally, Barclays PLC increased its stake in shares of Actinium Pharmaceuticals by 323.0% during the 3rd quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after purchasing an additional 32,784 shares during the last quarter. 27.50% of the stock is currently owned by institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).